-
[ITP changed because of you] Issue 39
Time of Update: 2022-08-20
"Clinical practice sharingCase 2 basic information:Sex: MaleAge: 42 Initial platelet level: 31×10 9 /LHormone insufficiency: Hormone ineffectiveThe specific medication regimen and medication duration of the previous case (before the use of second-line drugs):Drug name and dose: methylprednisolone 40mg qdDuration of medication: 1 weekTable 2 Case 2 follow-up and efficacy evaluation recordsNote: Both corticosteroids and eltrombopag are administered once daily (qd) .
-
[ITP changes because of you] Issue 38
Time of Update: 2022-08-20
"Clinical practice sharingCase 3 basic information:Sex: MaleAge: 90Initial platelet level: 23×10 9 /L Hormone Poor Situation: Hormone DependenceThe specific medication regimen and medication duration of the previous case (before the use of second-line drugs):Drug name and dosage: Dexamethasone 40mg qdDuration of medication: 3 weeksTable 3 Case 3 follow-up and efficacy evaluation recordsNote: Both corticosteroids and eltrombopag are administered once daily (qd) .
-
[ITP changes because of you] Issue 35
Time of Update: 2022-08-20
”Clinical practice sharingCase 1 basic information:Gender: FemaleAge: 27Initial platelet level: 8×10 9 /L Hormone insufficiency: Hormone ineffectiveThe specific medication regimen and medication duration of the previous case (before the use of second-line drugs):Drug name and dosage: Dexamethasone 40mg qdDuration of medication: less than 1 weekTable 1 Case 1 follow-up and efficacy evaluation recordsNote: Both corticosteroids and eltrombopag are administered once daily (qd) .
-
Microclassroom Issue 8 Prof. Jiang Hua: Definition, Mechanism, Diagnosis and Treatment of MGRS
Time of Update: 2022-08-20
MED-DAR-CN-0774 Content Approved Date: 8/11/2022For reference only by medical and pharmaceutical professionals, reproduction and dissemination are strictly prohibitedEdit: Arya Reviewer: Moon Typesetting: siqili Execution: molyClick "Read the original text" to see more contentThere are many types of monoclonal immunoglobulin-related diseases, often involving the kidneys, heart and other organs .
-
[ITP changes because of you] Issue 37
Time of Update: 2022-08-20
"Clinical practice sharingCase 4 Basic information:Gender: FemaleAge: 67Initial platelet level: 32×10 9 /LHormone Poor Situation: Hormone DependenceThe specific medication regimen and medication duration of the previous case (before the use of second-line drugs):Drug name and dosage: Prednisone 40mgDuration of medication: 4 weeks Table 4 Case 4 follow-up and efficacy evaluation recordsNote: Both corticosteroids and eltrombopag are administered once daily (qd) .
-
【Nuohe is with you, easy to love】 With a PK weapon and a strategy of benefiting the people, Turoctog alfa helps protect the light of normal life for hemophiliacs
Time of Update: 2022-08-20
Figure 2 Guidelines recommend that the diagnosis and treatment of hemophilia follow the principle of individualized treatmentFigure 3 Chua's formula content and applicationFigure 4 Turoctocog alfa individualized application and its advantagesVerified from multiple perspectives, Turoctocog alfa is safe, portable, effective and beneficial to the people, benefiting many patients with hemophiliaFVIII replacement therapy remains the standard treatment for hemophilia A, and the advent of recombinant human FVIII has had a profound impact on this treatment regimen .
-
HAEMOPHILIA: Which part of the blood in the knee joint is responsible for its harmful effects?
Time of Update: 2022-08-19
Therefore, a study aimed to investigate which blood components contribute to the development of joint damage caused by intra-articular hemorrhage of the knee joint in rabbits .
-
Signal Transduct Target Ther: Human umbilical cord blood mesenchymal stem cells for the treatment of psoriasis
Time of Update: 2022-08-19
After UMSCT treatment in psoriasis patients, the frequencies of Tregs and CD4+ memory T cells in peripheral blood were significantly increased, while the frequencies of helper T cells (Th)17 and CD4+ naive T cells were significantly decreased .
-
[August 15th (Monday) 19:00 Starlight Yiyi] The senior special session is about to start!
Time of Update: 2022-08-19
In recent years, the research and application of CAR-T cell therapy has been in full swing around the world, and it has shown excellent therapeutic effects in a variety of hematological malignancies, making the clinical cure of hematological malignancies possible.
-
Change Donor Kidney Blood Type!
Time of Update: 2022-08-19
British researchers have successfully "changed" the blood type of human donor kidney tissue from type B to type O, which is known as "universal blood", which means that in theory, patients can transplant these kidneys without blood type restrictions .
-
The world's leading!
Time of Update: 2022-08-19
Results of a clinical study conducted by Fu Bin, deputy chief physician of the Department of Hematology, Xiangya Hospital, Central South University, in collaboration with the team of Liu Mingyao and Wu Yuxuan from a company in Shanghai, "CRISPR/Cas9-mediated BCL11A enhancer gene editing for the treatment of β0/β0 infusion-dependent β- Thalassemia", published as a monograph online in Nature Medicine (Q1, IF 87.
-
[August 17th (Wednesday) 19:10 Starlight Yiyi] CAR-T bridging case session is about to start!
Time of Update: 2022-08-19
The chairman of the conference, at the same time, we also invited many top experts in the domestic CAR-T field to give online speeches to conduct in-depth discussions and exchanges on relevant hot issues such as the real cases of ICATA® in China and the accessibility of CAR-T cell therapy to clinical cure .
-
Ann Hematol: Lowering platelet count threshold to 10,000/µL for safe preservation of blood products
Time of Update: 2022-08-19
Overall, lowering the minimum platelet threshold from 50,000/µL to 10,000/µL reduced prophylactic platelet and total blood product use, with no significant difference in bleeding associated with PICC insertion .
-
A case of IgG anti-Lea antibody detected
Time of Update: 2022-08-19
In order to ensure the safety of clinical blood transfusion, for patients with Lewis blood group antibodies, cross-matching blood tests should be carried out with saline, polybrene, and column agglutination methods.
-
Thromboelastography assists in the diagnosis of "hematuria in children"
Time of Update: 2022-08-19
Common factors causing prolonged APTT and PT, such as anticoagulation therapy, various chronic liver diseases, acute poisoning, history of hemorrhage since childhood, and history of familial bleeding disorders, were excluded after clinical communication .
-
Application of anti-CD20 monoclonal antibody in lymphoma
Time of Update: 2022-08-15
Yun Wang shared an article published in Blood Cancer Journal entitled "Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed /refractory follicular lymphoma: final analysis of a Phase Ib/II trial (octuzumab-atezolizumab-lenalidomide [G-atezo-len] in relapsed/refractory follicular lymphoma) [R/R FL]: Final Analysis of Phase Ib/II Trials)” article [1] .
-
Big coffee explores "Auspiciousness" | Professor Xu Wei and Professor Cen Hong: From the status quo to progress, talk about the new direction of diagnosis and treatment of follicular lymphoma
Time of Update: 2022-08-15
. With the improvement of Professor Cen Hong's understanding of the disease and the launch of a variety of new targeted drugs, the treatment mode of FL has gradually developed to a targeted, "chemo-free" regimen; the prognostic model is also based on the common clinical indicators prognostic model FL International.
-
Micro-Classroom Phase 3 Prof. Wang Chong: Multiple Myeloma Immune Microenvironment and Treatment of First Relapsed MM
Time of Update: 2022-08-15
. POLLUX is a multicenter, randomized, open-label Phase III clinical study of Dara combined with Rd regimen for relapsed or refractory multiple myeloma (RRMM), including a total of 569 patients with RRMM.
-
The clinical results of lentiviral gene therapy are positive, and the data on the treatment of rare diseases is outstanding
Time of Update: 2022-08-15
. ➤ Orchard Therapeutics Orchard Therapeutics' OTL-103 is an autologous hematopoietic stem cell gene therapy consisting of CD34+ cells transfected in vitro with a lentiviral vector encoding the Wiskott-Aldrich syndrome (WAS) gene, designed to treat Wiskott-Aldrich syndrome by a single injection.
-
[Blood Adv] Analysis of causes of death in low-grade B-cell lymphoma in the rituximab era - from a prospective cohort study
Time of Update: 2022-08-15
) were not clinically significantly different, and the pattern of causes of death was similar between the subgroups of patients diagnosed in 2002-2008 and those diagnosed in 2009-2015 In addition, lymphoma-related deaths (10-year estimate for men 9.
